LTS acquires Eitan Medical’s Sorrel wearable injection device business

2023-04-21

并购

The acquisition aligns with LTS' plans to expand its portfolio of drug delivery platforms by including Sorrel's large volume wearable injector technologies LTS has acquired drug delivery solutions provider Sorrel. (Credit: National Cancer Institute Cancer Institute on Unsplash) LTS LOHMANN Therapie-Systeme, a German pharmaceutical technology company, has acquired the Sorrel wearable injection device business from Israel-based Eitan Medical. The financial terms of the deal were not disclosed. The acquisition aligns with LTS’ plans to expand its portfolio of drug delivery platforms by including Sorrel’s large volume wearable injector technologies. LTS said that it will now be able to support pharma partners in the areas of large molecules and biologics. Eitan Medical is engaged in the production of advanced infusion therapy and drug delivery solutions to make drug delivery easier and safer. Sorrel has been offering connected, pre-filled, and pre-loaded wearable devices for the subcutaneous administration of large molecule medications. It enables patients living with chronic and high burden conditions to safely and efficiently self-administer medication without changing their daily routine. Eitan Medical CEO and chairman Boaz Eitan said: “The acquisition of Sorrel, that evolved to be a leader in its space comes as testament to Eitan Medical’s capabilities. “This transaction will allow us to focus on our core business Medication Delivery Solutions and continue to innovate in the drug delivery market.” LTS develops and produces drug delivery systems like oral thin films (OTF), transdermal patches (TTS), and micro array patches (MAP). The pharmaceutical technology company has more than 20 marketed products and a pipeline of more than 30 development projects that target multiple disease indications. LTS CEO Bas van Buijtenen said: “The acquisition of the Sorrel platform catapults LTS into the world of drug delivery for large molecules, and fulfils our mission to bring empowering solutions to patients that rely on cumbersome and expensive therapies requiring in-clinic administration or multiple injections. “Sorrel’s solutions set a new standard for performance, quality, reliability, and patient convenience in wearable injection devices. The Sorrel platform is now ready for commercial launch and will accelerate its scale-up within LTS, benefiting from LTS’s global reach and reputation.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构